Skip to main content
. 2021 Jul 22;3(8):440–448. doi: 10.1253/circrep.CR-21-0030

Figure 1.

Figure 1.

Least-squares (LS) mean (±SEM) changes in body weight in the canagliflozin (CAN) and standard diabetic therapy (STDT) groups. ***P<0.001 compared with baseline (ANCOVA); #P<0.05, ###P<0.001 compared with the STDT group (ANCOVA).